This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations after disease progression on or after an EGFR-TKI.
Medscape Medical News